ginger extract
Dietary Supplement2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
NCT Number: NCT03268655
Estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects..
Looking for future studies?
Notify Me50 year–75 year
All sexes
Interventional
Not applicable
Mayo Clinic Cancer Center, Albert Lea, Minnesota, United States
This is a pilot trial to evaluate the feasibility of conducting a large randomized trial and estimate the effects of ginger extract on the gut microbiome. The pilot study will recruit from multiple sites 95-100 subjects aged 50-75 years old who were diagnosed with colorectal adenoma within the last five years. There will be 47-50 subjects in the treatment group and 47-50 in the placebo group. The subjects will be randomized to receive either 2000 mg of ginger extract per day (1000 mg twice a day) or matching placebo.
Subjects will provide three stool specimens for analysis of the intestinal microbiome over a 12-week period at the following intervals: Week 0 (Day 1), Week 6, and Week 12. Although the gut microbiome is stable within a period of 1-2 months, a control arm will be included to account for potential dietary and other changes that may affect the gut microbiome. Gut microbiome composition - the presence, abundance, and diversity of bacterial taxa - will be derived by sequencing microbial 16S ribosomal RNA genes.
Primary Aims:
Aim 1 is to estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects.
Aim 2 will examine the correlation between the ginger-related changes in microbiome profile with the levels of circulating biomarkers: urinary Prostaglandin E (PGE) metabolites.
Hypothesis: In the ginger versus placebo arm, gut microbiome will shift towards a lower proportion of pro-inflammatory, bacteria associated with colorectal cancer (CRC) and higher proportion of anti-inflammatory, CRC-protective bacteria.
Secondary Aim:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
Time frame: Baseline to 6 Weeks
Fecal microbial diversity and the prevalence of specific taxa associated with colorectal cancer (e.g. Fusobacteria, butyrate producing bacteria) will be estimated at 6 weeks. The ginger-related changes in the prevalence of each taxon will be assessed individually and also combined into a microbiome index (the abundance of protective taxa will be included as a negative value).
Time frame: Baseline to 6 weeks
Urinary metabolite of Prostaglandin E2 (ng/mg of creatinine) will be measured before and after treatment with ginger. Changes in inflammatory markers will be correlated to changes in the microbial diversity and the microbiome composition
Time frame: Baseline to 12 weeks
Beta-diversity will be compared between three time points: baseline, 6 Weeks and 12 Weeks.
University of Minnesota
Other
Pilot Trial to Examine the Effect of Ginger on the Gut Microbiome (GINGER)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07678099
Breast Cancer, Breast Diseases
Istanbul, Uskudar, Turkey (Türkiye)
View Trial DetailsNCT06979232
Colorectal Adenoma
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT07398820
Behavior, Colonic Diseases
Las Condes, Santiago Metropolitan, Chile
View Trial DetailsNCT07321548
Colonic Diseases, Colorectal Adenoma
Hong Kong
View Trial Details